COVID-19 taskforce publishes new risk classification tool


Monday, 21 March, 2022

COVID-19 taskforce publishes new risk classification tool

The National COVID-19 Clinical Evidence Taskforce (NCCET) has developed a risk classification tool to guide clinicians making decisions about which people are most likely to benefit from drug treatments.

While the available evidence is not sufficient to enable the Taskforce to determine which individual patients are most likely to benefit from treatment, the recommended drugs are likely to be most effective in preventing severe illness and mortality in those people who are at highest risk of these outcomes.

The risk of developing severe illness is higher in Aboriginal and Torres Strait Islander people due to inequity arising from social determinants of health.

The examples in the matrix are based on the clinical expertise of the Taskforce and are not definitive nor exhaustive. Clinicians should also consider whether people are unlikely to be able to access higher level care due to geographical remoteness or other factors. Feedback for the tool can be sent to guidelines@covid19evidence.net.au.

Related News

$12m for homegrown heart disease and diabetes innovations

$12 million in federal funding has been announced for the development of new Australian-made...

National cancer screening program marks first in almost 20 years

From 1 July, the National Lung Cancer Screening Program will commence — marking the first...

Doctor deregistered after botched facelift calls for ambulance

A Queensland doctor has been deregistered after a botched cosmetic surgery procedure left a...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd